| |

Predicting Opioid Addiction in Mesothelioma Patients

opioid addiction among mesothelioma patients

New research suggests that it may be possible to predict which mesothelioma patients are at risk for opioid addiction.

The research comes from the University of California. Scientists analyzed more than a hundred thousand cancer cases to come up with a list of risk factors for opioid addiction.

The information could help doctors select other, less dangerous ways of managing pain in high risk mesothelioma patients.  

Mesothelioma Pain and Opioid Addiction

Chest pain is a symptom of pleural mesothelioma. People with peritoneal mesothelioma may experience abdominal pain. As the disease progresses or lung fluid builds up, that pain can impact quality of life. Many mesothelioma patients also experience pain after surgery. 

Managing pain is a significant part of care for patients with mesothelioma or other types of cancer. Opioid drugs like fentanyl, methadone, and morphine are powerful pain relievers. But they can also lead to opioid addiction, especially for certain people. 

The US Department of Health and Human Services says 42,000 people died from opioid overdoses in 2016. An estimated 40 percent of those deaths involved prescription drugs. 

Other studies exist on opioid addiction risk. But the University of California researchers say there is not enough data on cancer-specific pain and opioids. 

Assessing the Risks for Cancer Patients

The research team conducted a retrospective study of 106,732 cancer survivors in the Veterans Administration database. They excluded patients with hematologic cancers (like lymphoma or leukemia) or skin cancer.

They determined how many of the patients ended up using opioids long-term, how many abused opioids, and how many were hospitalized for overdoses.

The researchers used the data to compile a list of risk factors for opioid addiction among cancer patients. “A multivariable logistic regression model was used to identify patient, cancer, and treatment risk factors for persistent opioid use,” they write.

Who is at Risk from Opioids?

The study showed that 8.3 percent of cancer patients had “persistent opioid use”, putting them at higher risk for opioid addiction. The rate of persistent use was highest among people who had never had an opioid prescription before.

The rate of opioid addiction or abuse was 2.9 percent overall and 2.1 percent in the opioid-naive patients.

Patients at lowest risk for opioid addiction included 

  • Older patients
  • Employed patients
  • African Americans
  • Patients living in higher-income zip codes

High risk factors included

  • History of alcoholism
  • History of drug abuse
  • Depression
  • Multiple health problems (comorbidities)

The researchers conducted independent tests to validate their findings. “An independent test set showed a high level of accuracy in predicting persistent opioid use, future diagnoses of opioid abuse or dependence, and admission for opioid abuse or toxicity,” concludes the report.

About 2,500 people receive a mesothelioma diagnosis in the US each year. Opioid prescriptions are “standard of care” for mesothelioma surgery patients

A 2018 study in JAMA Oncology suggested that minimally invasive lung cancer surgery could reduce the risk of opioid addiction in by reducing pain.

Source:

Vitzthum, L, et al, “Predicting Persistent Opioid Use, Abuse and Toxicity Among Cancer Survivors”, September 1, 2019, Radiation Oncology, https://www.redjournal.org/article/S0360-3016(19)31359-8/fulltext

Tuminello, S, et al, “Opioid Use After Open Resection or Video-Assisted Thoracoscopic Surgery for Early-Stage Lung Cancer”, November 2018, JAMA Oncology, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584254/

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…